author_facet DeSantis, Carol E.
Kramer, Joan L.
Jemal, Ahmedin
DeSantis, Carol E.
Kramer, Joan L.
Jemal, Ahmedin
author DeSantis, Carol E.
Kramer, Joan L.
Jemal, Ahmedin
spellingShingle DeSantis, Carol E.
Kramer, Joan L.
Jemal, Ahmedin
CA: A Cancer Journal for Clinicians
The burden of rare cancers in the United States
Oncology
Hematology
author_sort desantis, carol e.
spelling DeSantis, Carol E. Kramer, Joan L. Jemal, Ahmedin 0007-9235 1542-4863 Wiley Oncology Hematology http://dx.doi.org/10.3322/caac.21400 <jats:title>Abstract</jats:title><jats:p>There are limited published data on the burden of rare cancers in the United States. By using data from the North American Association of Central Cancer Registries and the Surveillance, Epidemiology, and End Results program, the authors provide information on incidence rates, stage at diagnosis, and survival for more than 100 rare cancers (defined as an incidence of fewer than 6 cases per 100,000 individuals per year) in the United States. Overall, approximately 20% of patients with cancer in the United States are diagnosed with a rare cancer. Rare cancers make up a larger proportion of cancers diagnosed in Hispanic (24%) and Asian/Pacific Islander (22%) patients compared with non‐Hispanic blacks (20%) and non‐Hispanic whites (19%). More than two‐thirds (71%) of cancers occurring in children and adolescents are rare cancers compared with less than 20% of cancers diagnosed in patients aged 65 years and older. Among solid tumors, 59% of rare cancers are diagnosed at regional or distant stages compared with 45% of common cancers. In part because of this stage distribution, 5‐year relative survival is poorer for patients with a rare cancer compared with those diagnosed with a common cancer among both males (55% vs 75%) and females (60% vs 74%). However, 5‐year relative survival is substantially higher for children and adolescents diagnosed with a rare cancer (82%) than for adults (46% for ages 65‐79 years). Continued efforts are needed to develop interventions for prevention, early detection, and treatment to reduce the burden of rare cancers. Such discoveries can often advance knowledge for all cancers. CA Cancer J Clin 2017. © <jats:bold>2017 American Cancer Society</jats:bold>. <jats:bold>CA Cancer J Clin 2017;67:261–272.</jats:bold> <jats:bold>© 2017 American Cancer Society.</jats:bold></jats:p> The burden of rare cancers in the United States CA: A Cancer Journal for Clinicians
doi_str_mv 10.3322/caac.21400
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzMyMi9jYWFjLjIxNDAw
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzMyMi9jYWFjLjIxNDAw
institution DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
imprint Wiley, 2017
imprint_str_mv Wiley, 2017
issn 0007-9235
1542-4863
issn_str_mv 0007-9235
1542-4863
language English
mega_collection Wiley (CrossRef)
match_str desantis2017theburdenofrarecancersintheunitedstates
publishDateSort 2017
publisher Wiley
recordtype ai
record_format ai
series CA: A Cancer Journal for Clinicians
source_id 49
title The burden of rare cancers in the United States
title_unstemmed The burden of rare cancers in the United States
title_full The burden of rare cancers in the United States
title_fullStr The burden of rare cancers in the United States
title_full_unstemmed The burden of rare cancers in the United States
title_short The burden of rare cancers in the United States
title_sort the burden of rare cancers in the united states
topic Oncology
Hematology
url http://dx.doi.org/10.3322/caac.21400
publishDate 2017
physical 261-272
description <jats:title>Abstract</jats:title><jats:p>There are limited published data on the burden of rare cancers in the United States. By using data from the North American Association of Central Cancer Registries and the Surveillance, Epidemiology, and End Results program, the authors provide information on incidence rates, stage at diagnosis, and survival for more than 100 rare cancers (defined as an incidence of fewer than 6 cases per 100,000 individuals per year) in the United States. Overall, approximately 20% of patients with cancer in the United States are diagnosed with a rare cancer. Rare cancers make up a larger proportion of cancers diagnosed in Hispanic (24%) and Asian/Pacific Islander (22%) patients compared with non‐Hispanic blacks (20%) and non‐Hispanic whites (19%). More than two‐thirds (71%) of cancers occurring in children and adolescents are rare cancers compared with less than 20% of cancers diagnosed in patients aged 65 years and older. Among solid tumors, 59% of rare cancers are diagnosed at regional or distant stages compared with 45% of common cancers. In part because of this stage distribution, 5‐year relative survival is poorer for patients with a rare cancer compared with those diagnosed with a common cancer among both males (55% vs 75%) and females (60% vs 74%). However, 5‐year relative survival is substantially higher for children and adolescents diagnosed with a rare cancer (82%) than for adults (46% for ages 65‐79 years). Continued efforts are needed to develop interventions for prevention, early detection, and treatment to reduce the burden of rare cancers. Such discoveries can often advance knowledge for all cancers. CA Cancer J Clin 2017. © <jats:bold>2017 American Cancer Society</jats:bold>. <jats:bold>CA Cancer J Clin 2017;67:261–272.</jats:bold> <jats:bold>© 2017 American Cancer Society.</jats:bold></jats:p>
container_issue 4
container_start_page 261
container_title CA: A Cancer Journal for Clinicians
container_volume 67
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792347431993606151
geogr_code not assigned
last_indexed 2024-03-01T17:55:08.906Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+burden+of+rare+cancers+in+the+United+States&rft.date=2017-07-08&genre=article&issn=1542-4863&volume=67&issue=4&spage=261&epage=272&pages=261-272&jtitle=CA%3A+A+Cancer+Journal+for+Clinicians&atitle=The+burden+of+rare+cancers+in+the+United+States&aulast=Jemal&aufirst=Ahmedin&rft_id=info%3Adoi%2F10.3322%2Fcaac.21400&rft.language%5B0%5D=eng
SOLR
_version_ 1792347431993606151
author DeSantis, Carol E., Kramer, Joan L., Jemal, Ahmedin
author_facet DeSantis, Carol E., Kramer, Joan L., Jemal, Ahmedin, DeSantis, Carol E., Kramer, Joan L., Jemal, Ahmedin
author_sort desantis, carol e.
container_issue 4
container_start_page 261
container_title CA: A Cancer Journal for Clinicians
container_volume 67
description <jats:title>Abstract</jats:title><jats:p>There are limited published data on the burden of rare cancers in the United States. By using data from the North American Association of Central Cancer Registries and the Surveillance, Epidemiology, and End Results program, the authors provide information on incidence rates, stage at diagnosis, and survival for more than 100 rare cancers (defined as an incidence of fewer than 6 cases per 100,000 individuals per year) in the United States. Overall, approximately 20% of patients with cancer in the United States are diagnosed with a rare cancer. Rare cancers make up a larger proportion of cancers diagnosed in Hispanic (24%) and Asian/Pacific Islander (22%) patients compared with non‐Hispanic blacks (20%) and non‐Hispanic whites (19%). More than two‐thirds (71%) of cancers occurring in children and adolescents are rare cancers compared with less than 20% of cancers diagnosed in patients aged 65 years and older. Among solid tumors, 59% of rare cancers are diagnosed at regional or distant stages compared with 45% of common cancers. In part because of this stage distribution, 5‐year relative survival is poorer for patients with a rare cancer compared with those diagnosed with a common cancer among both males (55% vs 75%) and females (60% vs 74%). However, 5‐year relative survival is substantially higher for children and adolescents diagnosed with a rare cancer (82%) than for adults (46% for ages 65‐79 years). Continued efforts are needed to develop interventions for prevention, early detection, and treatment to reduce the burden of rare cancers. Such discoveries can often advance knowledge for all cancers. CA Cancer J Clin 2017. © <jats:bold>2017 American Cancer Society</jats:bold>. <jats:bold>CA Cancer J Clin 2017;67:261–272.</jats:bold> <jats:bold>© 2017 American Cancer Society.</jats:bold></jats:p>
doi_str_mv 10.3322/caac.21400
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzMyMi9jYWFjLjIxNDAw
imprint Wiley, 2017
imprint_str_mv Wiley, 2017
institution DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15
issn 0007-9235, 1542-4863
issn_str_mv 0007-9235, 1542-4863
language English
last_indexed 2024-03-01T17:55:08.906Z
match_str desantis2017theburdenofrarecancersintheunitedstates
mega_collection Wiley (CrossRef)
physical 261-272
publishDate 2017
publishDateSort 2017
publisher Wiley
record_format ai
recordtype ai
series CA: A Cancer Journal for Clinicians
source_id 49
spelling DeSantis, Carol E. Kramer, Joan L. Jemal, Ahmedin 0007-9235 1542-4863 Wiley Oncology Hematology http://dx.doi.org/10.3322/caac.21400 <jats:title>Abstract</jats:title><jats:p>There are limited published data on the burden of rare cancers in the United States. By using data from the North American Association of Central Cancer Registries and the Surveillance, Epidemiology, and End Results program, the authors provide information on incidence rates, stage at diagnosis, and survival for more than 100 rare cancers (defined as an incidence of fewer than 6 cases per 100,000 individuals per year) in the United States. Overall, approximately 20% of patients with cancer in the United States are diagnosed with a rare cancer. Rare cancers make up a larger proportion of cancers diagnosed in Hispanic (24%) and Asian/Pacific Islander (22%) patients compared with non‐Hispanic blacks (20%) and non‐Hispanic whites (19%). More than two‐thirds (71%) of cancers occurring in children and adolescents are rare cancers compared with less than 20% of cancers diagnosed in patients aged 65 years and older. Among solid tumors, 59% of rare cancers are diagnosed at regional or distant stages compared with 45% of common cancers. In part because of this stage distribution, 5‐year relative survival is poorer for patients with a rare cancer compared with those diagnosed with a common cancer among both males (55% vs 75%) and females (60% vs 74%). However, 5‐year relative survival is substantially higher for children and adolescents diagnosed with a rare cancer (82%) than for adults (46% for ages 65‐79 years). Continued efforts are needed to develop interventions for prevention, early detection, and treatment to reduce the burden of rare cancers. Such discoveries can often advance knowledge for all cancers. CA Cancer J Clin 2017. © <jats:bold>2017 American Cancer Society</jats:bold>. <jats:bold>CA Cancer J Clin 2017;67:261–272.</jats:bold> <jats:bold>© 2017 American Cancer Society.</jats:bold></jats:p> The burden of rare cancers in the United States CA: A Cancer Journal for Clinicians
spellingShingle DeSantis, Carol E., Kramer, Joan L., Jemal, Ahmedin, CA: A Cancer Journal for Clinicians, The burden of rare cancers in the United States, Oncology, Hematology
title The burden of rare cancers in the United States
title_full The burden of rare cancers in the United States
title_fullStr The burden of rare cancers in the United States
title_full_unstemmed The burden of rare cancers in the United States
title_short The burden of rare cancers in the United States
title_sort the burden of rare cancers in the united states
title_unstemmed The burden of rare cancers in the United States
topic Oncology, Hematology
url http://dx.doi.org/10.3322/caac.21400